November 15, 2011
BMS to Expand Access to Reyataz in Brazil
Bristol-Myers Squibb (BMS) will expand access to its HIV drug Reyataz (atazanavir) in Brazil, according to a BMS statement. The pharmaceutical company has signed a technology transfer agreement with the Brazilian Ministry of Health, which will enable the Brazilian government to locally manufacture and distribute 200 mg and 300 mg capsules of Reyataz.
To read the BMS statement, click here.
Search: Brazil, Bristol-Myers Squibb, Reyataz, Brazilian Ministry of Health
Scroll down to comment on this story.
Show comments (0 total)
[Go to top]